Skip to main content
Ocumension Therapeutics logo

Ocumension Therapeutics — Investor Relations & Filings

Ticker · 1477 ISIN · KYG674111011 LEI · 5493000USURI3SIL4Z85 HKEX Manufacturing
Open in API
Filings indexed 459 across all filing types
Latest filing 2024-09-29 Proxy Solicitation & In…
Country KY Cayman Islands
Listing HKEX 1477

About Ocumension Therapeutics

http://www.ocumension.com

Ocumension Therapeutics is an ophthalmic pharmaceutical platform company dedicated to the research, development, and commercialization of first-in-class or best-in-class therapeutics. The company focuses on providing comprehensive treatment solutions for Chinese patients suffering from ocular diseases. Ocumension has established a complete ophthalmic drug product line, currently holding 20 drug assets covering both anterior and posterior segments of the eye. Its portfolio addresses major conditions such as chronic non-infectious uveitis, infective and allergic conjunctivitis, and diabetic macular edema. The company employs a strategy combining continuous scientific innovation, independent R&D, and strategic alliances to sustain the supply of innovative products across the ophthalmology field.

Recent filings

Filing Released Lang Actions
(1) VERY SUBSTANTIAL ACQUISITION IN RELATION TO ACQUISITION OF TRANSFERRED PRODUCTS, IN-LICENSING OF LICENSED PRODUCTS AND PROPOSED ISSUE OF CONSIDERATION SHARES UNDER SPECIFIC MANDATE&#x3b; (2) CONTI
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a circular from Ocumension Therapeutics dated September 30, 2024, concerning a very substantial acquisition, continuing connected transactions, and a notice of an Extraordinary General Meeting (EGM). It includes detailed definitions, letters from the board, independent financial advisor, financial information, management discussion and analysis, valuation report, unaudited financial information, pro forma financial information, assurance report, profit forecast letters, general information, and the notice of the EGM itself. The presence of a proxy form and detailed explanatory materials for shareholders to consider and vote on at the EGM indicates this is a proxy solicitation and information statement document. It is not a full annual or interim report, nor a simple announcement or regulatory filing. The document's purpose is to provide shareholders with information to make informed voting decisions at the EGM, which aligns with the Proxy Solicitation & Information Statement (PSI) category.
2024-09-29 English
CLOSURE OF REGISTER OF MEMBERS FOR THE EXTRAORDINARY GENERAL MEETING TO BE HELD ON OCTOBER 16, 2024
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is an announcement regarding the closure of the register of members for an upcoming Extraordinary General Meeting (EGM) scheduled on October 16, 2024. It references the purpose of the EGM and details about share transfer deadlines for shareholders to be eligible to attend and vote. The document does not contain financial statements, audit information, or detailed report content. It is a notice related to shareholder meeting logistics and voting eligibility, not the meeting materials or voting results themselves. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA) or possibly a Regulatory Filing (RNS). However, since it specifically concerns the closure of the register for voting eligibility ahead of the EGM, it aligns more closely with DVA, which covers official announcements related to shareholder voting rights and meeting preparations. The document length is short (2665 characters), and it is an announcement rather than a report or transcript. Hence, the classification is DVA with high confidence.
2024-09-27 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares or treasury shares, including share buybacks and on-market sales of treasury shares. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) and provides detailed data on share repurchases, including dates, prices, and quantities. The document also includes confirmations regarding compliance with listing rules and regulatory requirements. This type of filing is a regulatory disclosure about share repurchases and treasury share transactions, which fits the category of Transaction in Own Shares (POS). The document is substantive and detailed, not merely an announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). Therefore, the correct classification is POS with high confidence.
2024-09-26 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares or treasury shares, including share buybacks and on-market sales of treasury shares. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) and provides detailed data on share repurchases, including dates, prices, and quantities. The document also includes confirmations of compliance with listing rules and regulatory requirements. This type of filing is a regulatory disclosure about share repurchases and treasury share transactions, which fits the category of 'Transaction in Own Shares' (POS). The document is substantive and detailed, not merely an announcement or certification, so it is not classified as RNS or RPA. Therefore, the correct classification is POS with high confidence.
2024-09-25 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued shares or treasury shares, including share buybacks and on-market sales of treasury shares. It references specific listing rules from the Hong Kong Stock Exchange (Main Board Rules and GEM Rules) and details repurchase transactions, share counts, prices, and confirmations of compliance with listing rules. The content is regulatory in nature, reporting share repurchase activity and related confirmations, but does not contain financial statements or detailed financial performance data. It is a formal disclosure of share transactions rather than a financial report or earnings release. Therefore, it fits best under the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares.
2024-09-24 English
VOLUNTARY ANNOUNCEMENT NEW DRUG APPLICATION OF OT-502 ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ocumension Therapeutics regarding the acceptance of a new drug application by the National Medical Products Administration in China. It provides a business update about the regulatory progress of a drug (OT-502) and includes a cautionary statement to investors. The document is relatively short (2892 characters) and does not contain financial data, detailed financial performance, or regulatory certifications. It is an announcement of a business development rather than a financial report or regulatory filing. Therefore, it fits best into the category of a general regulatory or business update announcement, which aligns with the Regulatory Filings (RNS) category as a fallback for miscellaneous announcements that do not fit other specific categories.
2024-09-23 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.